AbbVie Gets Another Ulcerative Colitis Contender via $137M Landos Acquisition
AbbVie already has blockbuster drugs for ulcerative colitis, but that isn’t stopping the pharmaceutical giant from trying to expand its scope in this disease. To that end, the company is...